封面
市場調查報告書
商品編碼
1454250

橋本甲狀腺炎治療藥物的全球市場:按藥物類型、按特性、按最終用戶、按地區

Global Hashimoto's Thyroiditis Drug Market, By Drug Type, By Features, By End User, By Geography .

出版日期: | 出版商: Coherent Market Insights | 英文 192 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2023年,全球橋本甲狀腺炎治療市值為21.8億美元,預計2024年至2031年年複合成長率為5.7%,到2031年將達到34億美元。

報告範圍 報告詳情
基準年 2023年 2023/2024年市場規模 21.8億美元
實際資料 2019-2023 預測期 2024-2031
預測期間2023/2024 至2030/2031年年複合成長率: 5.70% 2030/2031價值預測 34億美元
圖 1.2023年橋本甲狀腺炎治療藥物依地區分類的全球市場佔有率(%)
全球橋本甲狀腺炎藥物市場-IMG1

橋本氏甲狀腺炎,又稱為慢性淋巴球性甲狀腺炎,是一種甲狀腺受到人體免疫系統攻擊的長期自體免疫疾病。主要症狀包括頸部甲狀腺腫、疲勞、不明原因的體重增加和對寒冷敏感。甲狀腺機能低下症是美國甲狀腺功能減退症最常見的原因之一,影響約 1,400 萬美國,每年花費數十億美元的治療費用。有多種藥物可用於治療甲狀腺機能低下症,包括替代甲狀腺激素的左旋甲狀腺素、抑制免疫反應的皮質類固醇以及其他症狀管理藥物。由於發病率和整體醫療費用的上升,預計橋本甲狀腺炎治療市場在未來幾年將顯著成長。

市場動態:

橋本的甲狀腺炎治療市場受到全球自體免疫疾病盛行率上升、老年人口增加以及對該疾病及其治療認知不斷提高的推動。根據美國生物技術資訊中心(NCBI)2023年發表的一篇論文,在美國和碘攝取充足的地區,橋本氏症是6歲以後甲狀腺機能低下症最常見的原因。在全球範圍內,男性發病率估計為每年每 1,000 人 0.8 例,女性每年每 1,000 人發病率為 3.5 例。然而,新興市場缺乏認知、生物製藥成本高和社會恥辱繼續抑制市場成長。同時,標靶治療、聯合治療和線上疾病社群的發展為該領域的參與者創造商機。市場擴大採用口服藥物而不是手術干預。公司投資研發,以開發具有更高功效和安全性的新配方。

本研究的主要特點

  • 本報告對全球橋本氏甲狀腺炎治療藥物市場進行了詳細分析,並提供了以2023年為基準年的預測期(2024-2031年)的市場規模和年複合成長率(CAGR%) 。
  • 說明了各個細分市場的潛在收益成長機會,並為該市場提供了一系列有吸引力的投資提案。
  • 提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的主要考察。
  • 根據公司亮點、產品系列、主要亮點、業績和策略等參數列出了全球橋本甲狀腺炎治療藥物市場的主要公司概況。
  • 本研究涵蓋的主要企業包括AbbVie Inc.、Merck &Co.、Allergan、Amneal Pharmaceuticals.、Lannett Company、Mylan Pharmaceuticals、Pfizer、Akorn Pharmaceuticals、Acella Pharmaceuticals、Jerome Stevens Pharmaceuticals和其他知名公司。
  • 本報告的見解將幫助負責人和公司經營團隊就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
  • 全球橋本甲狀腺炎治療藥物市場報告迎合了該行業的各個相關人員,如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
  • 透過用於分析全球橋本甲狀腺炎治療藥物市場的各種策略矩陣,將促進相關人員的決策。

目錄

第1章 研究目的與前提

  • 研究目標
  • 先決條件
  • 簡稱

第2章 市場展望

  • 報告說明
    • 市場定義和範圍
  • 執行摘要
  • Coherent Opportunity Map(COM)

第3章 市場動態、法規及趨勢分析

  • 市場動態
  • 影響分析
  • 主要亮點
  • 監管場景
  • 產品發布/核准
  • PEST分析
  • 波特的分析
  • 併購場景

第4章 橋本甲狀腺炎治療藥物的全球市場-冠狀病毒(COVID-19)大流行的影響

  • 新型冠狀病毒感染疾病(COVID-19)的流行病學
  • 供需面分析
  • 經濟影響

第5章 2019-2031年全球橋本甲狀腺炎治療藥物市場,依藥物類型

  • 甲狀腺荷爾蒙補充療法
  • 發炎藥
  • 抗甲狀腺藥物
  • 抗促泌素藥物
  • BETA受體阻斷劑
  • 鈣離子通道阻斷劑
  • 其他(補充品等)

第6章 全球橋本甲狀腺炎治療藥物市場,依給藥途徑,2019-2031

  • 口服
  • 胃腸外
  • 局部

第7章 2019-2031年全球橋本甲狀腺炎治療藥物市場,依劑型

  • 藥片
  • 膠囊
  • 軟凝膠
  • 乳膏
  • 其他(藥膏/其他)

第8章 2019-2031年全球橋本甲狀腺炎治療藥物市場,依通路

  • 醫院藥房
  • 零售藥房
  • 網路藥房

第9章 2019-2031年全球橋本甲狀腺炎治療藥物市場,依地區

  • 北美洲
  • 美國
  • 加拿大
  • 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
  • 歐洲
  • 德國
  • 英國
  • 西班牙
  • 法國
  • 義大利
  • 俄羅斯
  • 歐洲其他地區
  • 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • ASEAN
  • 其他亞太地區
  • 中東
  • GCC
  • 以色列
  • 其他中東地區
  • 非洲
  • 南非
  • 北非
  • 中部非洲

第10章 競爭格局

  • AbbVie Inc.
  • Merck & Co.
  • Amneal Pharmaceuticals.
  • Lannett Company
  • Mylan Pharmaceuticals
  • Pfizer
  • Akorn Pharmaceuticals
  • Acella Pharmaceuticals
  • Jerome Stevens Pharmaceuticals
  • Other Prominent Players

第11章 章節

  • 調查方法
  • 關於出版商
簡介目錄
Product Code: CMI6675

The global Hashimoto's thyroiditis drug market was valued at US$ 2.18 Bn in 2023 and is expected to reach US$ 3.40 Bn by 2031, growing at a compound annual growth rate (CAGR) of 5.7% from 2024 to 2031.

Report Coverage Report Details
Base Year: 2023 Market Size in 2023/2024: US$ 2.18 Bn
Historical Data for: 2019 to 2023 Forecast Period: 2024 - 2031
Forecast Period 2023/2024 to 2030/2031 CAGR: 5.70% 2030/2031 Value Projection: US$ 3.40 Bn
Figure 1. Global Hashimoto's Thyroiditis Drug Market Share (%), by Region, 2023
Global Hashimoto's Thyroiditis Drug Market - IMG1

Hashimoto's thyroiditis, also known as chronic lymphocytic thyroiditis, is a long-term autoimmune disease in which the thyroid gland is attacked by the body's immune system. Some of the major symptoms include goiter formation in the neck, fatigue, unexplained weight gain, and sensitivity to cold. It is one of the most common causes of hypothyroidism in the U.S., which it affecting about 14 million Americans and costs billions in treatment annually. A variety of drugs are being used for its management, such as levothyroxine, to replace thyroid hormones, corticosteroids to suppress the immune response, and other symptom management drugs. With increasing incidence rates and overall healthcare cost burden, the Hashimoto's thyroiditis drug market is poised to grow significantly in the coming years.

Market Dynamics:

The Hashimoto's thyroiditis drug market is driven by the rising prevalence of autoimmune diseases globally, growing geriatric population, increasing awareness about the condition, and its management. According to an article published in the National Center for Biotechnology Information (NCBI) in 2023, after age six, Hashimoto is the most common cause of hypothyroidism in the U.S. and in those areas of the world where iodine intake is adequate. Globally, the incidence is estimated to be 0.8 per 1,000 per year in men and 3.5 per 1,000 per year in women. However, lack of awareness in developing nations, high costs of biologic drugs, and social stigma continue to restrain the market growth. On the other hand, the development of targeted therapies, combination drug treatments and online disease communities have opened up opportunities for players in this space. The market is witnessing the rising adoption of oral medications over surgical interventions. Players are investing in R&D to develop novel formulations with improved efficacy and safety profiles.

Key Features of the Study:

  • This report provides an in-depth analysis of the global Hashimoto's thyroiditis drug market, and provides market size (US$ Bn) and Compound Annual Growth Rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
  • It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global Hashimoto's thyroiditis drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • The key companies covered as a part of this study include AbbVie Inc., Merck & Co., Allergan., Amneal Pharmaceuticals., Lannett Company, Mylan Pharmaceuticals, Pfizer, Akorn Pharmaceuticals, Acella Pharmaceuticals, Jerome Stevens Pharmaceuticals, and other prominent players
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global Hashimoto's thyroiditis drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Hashimoto's thyroiditis drug market

Detailed Segmentation:

  • By Drug Type
    • Thyroid hormone replacement therapy
    • Anti-inflammatory drugs
    • Antithyroid medications
    • Anti-cretin medications
    • Beta-blockers
    • Calcium channel blockers
    • Others (Supplements and Others)
  • By Route of Administration
    • Oral
    • Injections
    • Topical
  • By Dosage Form
    • Tablets
    • Capsules
    • Softgels
    • Creams
    • Others (Ointments and Others)
  • By End Users
    • Hospitals
    • Sleep Centers
    • Home Care Settings
    • Diagnostic Laboratories
  • By Region
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East
    • Africa
  • Top Companies in the Global Hashimoto's Thyroiditis Drug Market
    • AbbVie Inc.
    • Merck & Co.
    • Allergan
    • Amneal Pharmaceuticals.
    • Lannett Company
    • Mylan Pharmaceuticals
    • Pfizer
    • Akorn Pharmaceuticals
    • Acella Pharmaceuticals
    • Jerome Stevens Pharmaceuticals
    • Other Prominent Players

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Hashimoto's Thyroiditis Drug Market, By Drug Type
    • Global Hashimoto's Thyroiditis Drug Market, By Route of Administration
    • Global Hashimoto's Thyroiditis Drug Market, By Dosage Form
    • Global Hashimoto's Thyroiditis Drug Market, By Distribution Channel
    • Global Hashimoto's Thyroiditis Drug Market, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Opportunities
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Hashimoto's Thyroiditis Drug Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Hashimoto's Thyroiditis Drug Market, By Drug Type, 2019-2031, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Thyroid hormone replacement therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
  • Anti-inflammatory drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
  • Antithyroid medications
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
  • Anti-cretin medications
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
  • Beta-blockers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
  • Calcium channel blockers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
  • Others (Supplements and Others)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)

6. Global Hashimoto's Thyroiditis Drug Market, By Route of Administration, 2019-2031, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
  • Parenteral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
  • Topical
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)

7. Global Hashimoto's Thyroiditis Drug Market, By Dosage Form, 2019-2031, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Tablets
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
  • Capsules
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
  • Softgels
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
  • Creams
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
  • Others (Ointments and Others)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)

8. Global Hashimoto's Thyroiditis Drug Market, By Distribution Channel, 2019-2031, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)

9. Global Hashimoto's Thyroiditis Drug Market, By Region, 2019-2031, (US$ Bn)

  • Introduction
    • Market Share Analysis, By Region, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, For Region, 2020 - 2031
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Bn)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Bn)
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Bn)
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Bn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Bn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019-2031,(US$ Bn)
  • South Africa
  • North Africa
  • Central Africa

10. Competitive Landscape

  • AbbVie Inc.
  • Merck & Co.
  • Amneal Pharmaceuticals.
  • Lannett Company
  • Mylan Pharmaceuticals
  • Pfizer
  • Akorn Pharmaceuticals
  • Acella Pharmaceuticals
  • Jerome Stevens Pharmaceuticals
  • Other Prominent Players
  • Analyst Views

11. Section

  • Research Methodology
  • About us